QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NASDAQ:CMRX

Chimerix - CMRX Stock Forecast, Price & News

$1.77
-0.03 (-1.67%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.77
▼
$1.82
50-Day Range
$1.70
▼
$2.35
52-Week Range
$1.27
▼
$6.43
Volume
508,487 shs
Average Volume
610,053 shs
Market Capitalization
$155.83 million
P/E Ratio
1.01
Dividend Yield
N/A
Price Target
$8.50

Chimerix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
380.2% Upside
$8.50 Price Target
Short Interest
Healthy
3.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
0.45mentions of Chimerix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$5,685 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.97 to ($0.90) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

257th out of 1,049 stocks

Pharmaceutical Preparations Industry

124th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

CMRX stock logo

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

January 5, 2023 | finance.yahoo.com
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023 | thestreet.com
Why Chimerix (CMRX) Stock Is Tanking Today
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 29, 2022 | finance.yahoo.com
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?
November 14, 2022 | bizjournals.com
Hedge fund urges Durham drugmaker Chimerix to liquidate
November 10, 2022 | finance.yahoo.com
Rubric Capital Management Sends Letter to Chimerix Board of Directors
November 10, 2022 | finance.yahoo.com
Chimerix Responds to Rubric Capital Management
November 4, 2022 | finance.yahoo.com
Buy 3 of the Best Stocks by Using Net Income Ratio
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 3, 2022 | finance.yahoo.com
Chimerix (CMRX) Beats Q3 Earnings Estimates
November 3, 2022 | finance.yahoo.com
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
October 27, 2022 | finance.yahoo.com
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
October 11, 2022 | nasdaq.com
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates? - Nasdaq
October 5, 2022 | proactiveinvestors.com
Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia - Proactive Investors USA
October 5, 2022 | uk.investing.com
$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying By Benzinga - Investing.com UK
September 28, 2022 | bizjournals.com
Durham pharma nets $238M for smallpox drug with more payouts lined up - The Business Journals
September 27, 2022 | finance.yahoo.com
Emergent BioSolutions closes acquisition of smallpox drug from Chimerix
September 26, 2022 | globenewswire.com
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages - GlobeNewswire
September 26, 2022 | globenewswire.com
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions - GlobeNewswire
September 11, 2022 | nasdaq.com
We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully - Nasdaq
September 10, 2022 | finance.yahoo.com
Institutional investors own a significant stake of 49% in Chimerix, Inc. (NASDAQ:CMRX)
September 6, 2022 | benzinga.com
Chimerix (CMRX) – Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference - Benzinga
September 6, 2022 | finance.yahoo.com
Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 2, 2022 | nasdaq.com
Implied Volatility Surging for Chimerix (CMRX) Stock Options - Nasdaq
September 1, 2022 | finance.yahoo.com
Implied Volatility Surging for Chimerix (CMRX) Stock Options
August 31, 2022 | benzinga.com
(BVNRY), Chimerix (CMRX) – Testing, Treatment, and Vaccines are the Three Ways Companies Can Fight Monkey - Benzinga
August 31, 2022 | benzinga.com
Chimerex, Inc. (CMRX) – Chimerix's Return On Capital Employed Insights - Benzinga
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Company Calendar

Last Earnings
11/03/2022
Today
1/30/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMRX
CUSIP
N/A
CIK
1117480
Web
www.chimerix.com
Phone
(919) 806-1074
Fax
919-806-1146
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+380.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.75
Trailing P/E Ratio
1.01
Forward P/E Ratio
0.90
P/E Growth
N/A
Net Income
$-173,240,000.00
Net Margins
464.75%
Pretax Margin
465.22%
Return on Equity
147.04%
Return on Assets
119.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.44
Quick Ratio
16.44

Sales & Book Value

Annual Sales
$1.98 million
Price / Sales
78.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.79 per share
Price / Book
2.24

Miscellaneous

Outstanding Shares
88,040,000
Free Float
80,825,000
Market Cap
$155.83 million
Optionable
Optionable
Beta
1.17

Key Executives

  • Mr. Michael A. Sherman M.B.A. (Age 57)
    CEO, Pres & Director
    Comp: $987.2k
  • Mr. Michael T. Andriole M.B.A. (Age 50)
    Chief Bus. Officer, Sec. & CFO
    Comp: $616.9k
  • Dr. Allen S. Melemed M.B.A. (Age 59)
    M.D., Chief Medical Officer
    Comp: $622.17k
  • Mr. David Jakeman CPA (Age 45)
    Exec. Director of Fin. & Accounting and Principal Accounting Officer
  • Dr. Roy W. Ware
    Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier
    Chief Science Officer
  • Ms. Michelle LaSpaluto
    VP of Strategic Planning & Investor Relations
  • Dr. Michael A. Alrutz (Age 53)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Dr. Joshua E. Allen
    Chief Technology Officer of Imipridones

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.

What is Chimerix's stock price forecast for 2023?

3 analysts have issued 12-month price targets for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 378.9% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2023?

Chimerix's stock was trading at $1.86 at the beginning of 2023. Since then, CMRX shares have decreased by 4.6% and is now trading at $1.7750.
View the best growth stocks for 2023 here.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CMRX earnings forecast.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) posted its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.10 by $0.65. The biopharmaceutical company earned $32.56 million during the quarter, compared to the consensus estimate of $205.30 million. Chimerix had a trailing twelve-month return on equity of 147.04% and a net margin of 464.75%.

What other stocks do shareholders of Chimerix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.43%), Assenagon Asset Management S.A. (0.30%), Strs Ohio (0.09%), Clear Harbor Asset Management LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.78.

How much money does Chimerix make?

Chimerix (NASDAQ:CMRX) has a market capitalization of $156.27 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 1/30/2023 by MarketBeat.com Staff